Life Sciences

Anecdotal success stories and endless media attention have generated hype around the utility of GenAI. Deloitte has spent the last year not only thinking critically about the value of GenAI, but also implementing the technology, driving its adoption, and monitoring its value. This includes scaling dozens of AI and GenAI use cases for our life sciences clients and launching our own GenAI platform for our internal colleagues.

Nach Berechnungen verursacht die Gesundheitsbranche knapp vier Prozent der globalen und knapp fünf Prozent der deutschen CO2-Emissionen. Damit gehört der Gesundheitssektor zu den führenden CO2-Emittenten weltweit. Die Medizintechnik hat daran zusammen mit der Pharmaindustrie mit knapp zwei Dritteln den größten Anteil. Die Studie von Deloitte in Zusammenarbeit mit dem Bundesverband Medizintechnologie e.V. räsentiert die Ergebnisse einer Befragung von 104 Entscheidungsträgern aus Krankenhäusern in Deutschland mit dem Ziel, Denkanstöße zu vermitteln und Handlungsfelder zum Thema Nachhaltigkeit beim Einkauf von Medizintechnikprodukten aufzuzeigen.

The past 14 years have demonstrated that transformational change in R&D productivity is required to reverse the declining trends in returns across the biopharma industry and the ongoing challenge of continuing to deliver innovation to patients. Our latest report series "Measuring the return from pharmaceutical innovation" shows that this conclusion is more relevant than ever, given that companies are facing a more challenging regulatory landscape, growing cost pressures, declining peak sales, and difficulties in replenishing their pipelines, with the result that projected R&D returns continue to remain well below the cost of capital.

MedTech companies reporting quality and regulatory deficiencies are not only struggling to ensure patient safety. Such deficiencies and product recalls also have a long-term impact on a company's competitive financial performance. While stock markets did not seem to systematically penalize poor quality and regulatory compliance in the MedTech sector over the past decades, this has completely changed in recent years. In our Deloitte-paper, we discuss the reasons for this shift and illustrate how MedTech companies are responding with targeted investments.